Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,631,670
  • Shares Outstanding, K 661,299
  • Annual Sales, $ 2,392 M
  • Annual Income, $ 631,910 K
  • 60-Month Beta 0.97
  • Price/Sales 6.89
  • Price/Cash Flow 20.28
  • Price/Book 3.51
Trade GMAB with:

Options Overview Details

View History
  • Implied Volatility 46.64% ( -4.08%)
  • Historical Volatility 22.85%
  • IV Percentile 77%
  • IV Rank 33.01%
  • IV High 112.31% on 06/26/24
  • IV Low 14.29% on 05/10/24
  • Put/Call Vol Ratio 0.40
  • Today's Volume 7
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 646
  • Open Int (30-Day) 614

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.28
  • Number of Estimates 7
  • High Estimate 0.33
  • Low Estimate 0.26
  • Prior Year 0.30
  • Growth Rate Est. (year over year) -6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.53 +4.12%
on 07/02/24
28.56 -10.57%
on 06/06/24
-3.20 (-11.13%)
since 06/05/24
3-Month
24.53 +4.12%
on 07/02/24
30.41 -16.01%
on 05/15/24
-4.22 (-14.18%)
since 04/05/24
52-Week
24.53 +4.12%
on 07/02/24
42.72 -40.22%
on 07/28/23
-12.94 (-33.63%)
since 07/05/23

Most Recent Stories

More News
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

PFE : 28.05 (+1.26%)
ABBV : 167.25 (+2.08%)
JNJ : 146.48 (+0.54%)
RHHBY : 34.0300 (-0.23%)
GMAB : 25.54 (+1.55%)
AZN : 77.34 (+0.70%)
DSNKY : 35.6200 (+1.11%)
MRK : 126.45 (+0.48%)
LLY : 914.57 (+1.83%)
NVO : 142.37 (+2.52%)
Why Shares of Iovance Biotherapeutics Dropped Thursday

The biotech stock's lead therapy is looking at some competition.

SGEN : 228.74 (-0.07%)
GMAB : 25.54 (+1.55%)
IOVA : 7.28 (-1.49%)
Why Shares of Zai Lab Limited Were Jumping on Tuesday

Zai Lab's shares benefited from positive clinical trial news.

ZLAB : 17.32 (+0.58%)
SGEN : 228.74 (-0.07%)
GMAB : 25.54 (+1.55%)
Is AbbVie Still a Good Dividend Stock to Buy?

Find out if AbbVie can overcome sinking sales of its top-selling product.

ABT : 104.02 (+1.65%)
RHHBY : 34.0300 (-0.23%)
AMGN : 310.88 (+0.48%)
GMAB : 25.54 (+1.55%)
ABBV : 167.25 (+2.08%)
3 Things About Johnson & Johnson Every Smart Investor Knows

The company has been a strong value stock but faces big changes this year.

KVUE : 18.31 (unch)
AMGN : 310.88 (+0.48%)
GMAB : 25.54 (+1.55%)
JNJ : 146.48 (+0.54%)
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?

In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.

ABBV : 167.25 (+2.08%)
GMAB : 25.54 (+1.55%)
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCOREâ„¢...

ABBV : 167.25 (+2.08%)
GMAB : 25.54 (+1.55%)
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel...

GMAB : 25.54 (+1.55%)
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Genmab A/S (Nasdaq: GMAB):

GMAB : 25.54 (+1.55%)
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S (Nasdaq: GMAB) today announced the results from multiple clinical trials evaluating epcoritamab (DuoBody ® -CD3xCD20), an investigational subcutaneous bispecific antibody, alone or in...

GMAB : 25.54 (+1.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 25.44
2nd Resistance Point 25.36
1st Resistance Point 25.25
Last Price 25.54
1st Support Level 25.06
2nd Support Level 24.98
3rd Support Level 24.87

See More

52-Week High 42.72
Fibonacci 61.8% 35.77
Fibonacci 50% 33.63
Fibonacci 38.2% 31.48
Last Price 25.54
52-Week Low 24.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar